PL2217578T3 - Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanie - Google Patents
Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanieInfo
- Publication number
- PL2217578T3 PL2217578T3 PL08806565T PL08806565T PL2217578T3 PL 2217578 T3 PL2217578 T3 PL 2217578T3 PL 08806565 T PL08806565 T PL 08806565T PL 08806565 T PL08806565 T PL 08806565T PL 2217578 T3 PL2217578 T3 PL 2217578T3
- Authority
- PL
- Poland
- Prior art keywords
- triazolo
- pyridine
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
Links
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 title 1
- QLOWGDIISXJREF-UHFFFAOYSA-N [1,2,4]triazolo[1,5-c]pyrimidine Chemical class C1=CN=CN2N=CN=C21 QLOWGDIISXJREF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97879207P | 2007-10-10 | 2007-10-10 | |
| GBGB0719803.9A GB0719803D0 (en) | 2007-10-10 | 2007-10-10 | Therapeutic compounds and their use |
| EP08806565.1A EP2217578B9 (en) | 2007-10-10 | 2008-10-10 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
| PCT/GB2008/003428 WO2009047514A1 (en) | 2007-10-10 | 2008-10-10 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2217578T3 true PL2217578T3 (pl) | 2014-05-30 |
Family
ID=38787938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08806565T PL2217578T3 (pl) | 2007-10-10 | 2008-10-10 | Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanie |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8431596B2 (pl) |
| EP (1) | EP2217578B9 (pl) |
| CY (1) | CY1114911T1 (pl) |
| DK (1) | DK2217578T5 (pl) |
| ES (1) | ES2446298T3 (pl) |
| GB (1) | GB0719803D0 (pl) |
| HR (1) | HRP20140191T1 (pl) |
| PL (1) | PL2217578T3 (pl) |
| PT (1) | PT2217578E (pl) |
| SI (1) | SI2217578T1 (pl) |
| WO (1) | WO2009047514A1 (pl) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2288260A4 (en) | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| BRPI0909945A2 (pt) | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010189A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| TW201010977A (en) * | 2008-08-12 | 2010-03-16 | Takeda Pharmaceutical | Amide compound |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
| AU2011211410B2 (en) * | 2009-02-13 | 2013-01-31 | Fovea Pharmaceuticals Sa | [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors |
| SG173610A1 (en) * | 2009-02-13 | 2011-09-29 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| CN102459258B (zh) * | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| MX350217B (es) | 2010-05-25 | 2017-08-30 | Dow Agrosciences Llc | Proceso para la preparacion de 8-alcoxi [1,2,4] triazol [1,5-c] pirimidin-2-aminas substituidas-5. |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| AR081960A1 (es) * | 2010-06-22 | 2012-10-31 | Fovea Pharmaceuticals Sa | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012025186A1 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| EP2648728B1 (en) * | 2010-12-06 | 2016-04-27 | Cephalon, Inc. | Janus kinase 2 (jak2) inhibitor for the treatment of lupus |
| HRP20150517T1 (hr) * | 2011-04-21 | 2015-06-19 | Bayer Intellectual Property Gmbh | Triazolopiridini |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| RS55728B1 (sr) | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| KR20130091464A (ko) | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
| CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
| WO2013162061A1 (ja) * | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
| CA2878481A1 (en) | 2012-07-10 | 2014-01-16 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| RS56034B1 (sr) | 2013-06-11 | 2017-09-29 | Bayer Pharma AG | Derivati prolekova supstituisanih triazolopiridina |
| JP6527513B2 (ja) | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
| JP6496731B2 (ja) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Tamファミリーキナーゼ阻害剤としてのアミノピリジン誘導体 |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| CN103965202B (zh) * | 2014-05-21 | 2016-01-20 | 邹宏丽 | 二环稠合杂环化合物、其制备方法及用途 |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| EP3248980B1 (en) | 2015-01-20 | 2023-09-06 | Wuxi Fortune Pharmaceutical Co., Ltd | Jak inhibitor |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| ES2734048T3 (es) | 2015-04-29 | 2019-12-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidores de Janus cinasas (JAK) |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| ES2822748T3 (es) | 2015-05-29 | 2021-05-04 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibidor de cinasa Janus |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| CN108349979B (zh) | 2015-11-02 | 2021-04-09 | 詹森药业有限公司 | [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物 |
| WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
| MD3436461T2 (ro) | 2016-03-28 | 2024-05-31 | Incyte Corp | Compuși pirolotriazină ca inhibitori TAM |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Lsd1阻害剤の製剤 |
| CN106188041B (zh) * | 2016-06-29 | 2017-12-08 | 四川大学华西医院 | [1,2,4]三唑并[1,5‑a]吡啶衍生物 |
| WO2018000549A1 (zh) * | 2016-06-29 | 2018-01-04 | 四川大学华西医院 | [1,2,4]三唑并[1,5-a]吡啶衍生物及其晶型 |
| CN107759587B (zh) * | 2016-08-19 | 2021-01-26 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
| CN107880038B (zh) * | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
| JP6994029B2 (ja) * | 2016-10-26 | 2022-01-14 | ヤンセン ファーマシューティカ エヌ.ベー. | 融合アザヘテロ環状化合物、及びampa受容体調節因子としてのそれらの使用 |
| EP3532477B1 (en) * | 2016-10-26 | 2020-08-26 | Janssen Pharmaceutica NV | Fused bicylic pyridine compounds and their use as ampa receptor modulators |
| CN109890824B (zh) | 2016-11-02 | 2022-05-24 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| MY193511A (en) | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
| SI3687996T1 (sl) | 2017-09-27 | 2022-04-29 | Incyte Corporation | Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM |
| EP3695839A4 (en) | 2017-10-13 | 2021-07-14 | ONO Pharmaceutical Co., Ltd. | THERAPEUTIC AGENT WITH AXL INHIBITOR AS AN ACTIVE INGREDIENT FOR SOLID TUMORS |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| MD3813800T2 (ro) | 2018-06-29 | 2025-10-31 | Incyte Corp | Formulări de inhibitor al AXL/MER |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| EA202192389A1 (ru) * | 2019-03-30 | 2022-01-21 | Юникем Лабораторис Лимитед | Новый способ получения филготиниба и его промежуточных соединений |
| EP3950064A4 (en) * | 2019-04-03 | 2023-01-04 | Tera Stone Co., Ltd | THYMINE NUCLEOBASE BASED TRIAZOLOPYRIMIDINES AND PROCESS FOR THEIR PRODUCTION |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| EP3969639B1 (en) | 2019-05-13 | 2025-03-12 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| US20220274983A1 (en) * | 2019-08-06 | 2022-09-01 | Jiangsu Carephar Pharmaceutical Co., Ltd. | Jak kinase inhibitor and use thereof |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| WO2022007921A1 (zh) * | 2020-07-10 | 2022-01-13 | 北京范恩柯尔生物科技有限公司 | 三嗪类化合物及其组合物和用途 |
| CN114075188A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
| CN114075189A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 五元杂环并苯环类化合物及其制备方法和医药用途 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN116354955A (zh) * | 2021-12-28 | 2023-06-30 | 上海科胜药物研发有限公司 | 一种菲戈替尼的制备方法 |
| CN115819425A (zh) * | 2022-12-22 | 2023-03-21 | 五邑大学 | 一种三唑并六元氮杂环-2-胺类化合物及其制备方法和应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL105768C (pl) | 1959-02-25 | |||
| GB873223A (en) | 1959-04-13 | 1961-07-19 | Ici Ltd | Heterocyclic compounds |
| US3053844A (en) * | 1959-04-13 | 1962-09-11 | Ici Ltd | Mono-acyl derivatives of s-triazolo [2, 3-c] pyrimidines |
| US3046276A (en) * | 1959-06-15 | 1962-07-24 | Ici Ltd | S-triazolo-[2, 3-c] pyrimidine derivatives |
| GB897870A (en) | 1959-06-15 | 1962-05-30 | Ici Ltd | s-triazolo[2, 3-c]pyrimidine derivatives |
| US2963480A (en) * | 1959-12-29 | 1960-12-06 | Edward C Taylor | 6-pteridinehydrazine and amidrazone derivatives |
| US4579848A (en) * | 1983-07-28 | 1986-04-01 | American Cyanamid Company | 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines |
| NZ208996A (en) * | 1983-07-28 | 1989-08-29 | American Cyanamid Co | 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions |
| JPH04204441A (ja) | 1990-11-29 | 1992-07-24 | Konica Corp | 新規な染料を含有するハロゲン化銀写真感光材料 |
| FR2678618B1 (fr) * | 1991-07-05 | 1993-11-05 | Upsa Laboratoires | Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5358950A (en) * | 1991-07-05 | 1994-10-25 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| TR199800906T1 (xx) * | 1996-09-24 | 2000-02-21 | Dow Agrosciences Llc | N-($1,2,4]Triazoloazinil ) benzens�lfonamid ve piridins�lfonamid bile�ikleri ve bunlar�n herbisidler olarak kullan�mlar� |
| JPH10148903A (ja) | 1996-11-20 | 1998-06-02 | Konica Corp | 耐圧性の改良されたハロゲン化銀写真感光材料 |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| US6693116B2 (en) * | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| JP2003213152A (ja) | 2002-01-23 | 2003-07-30 | Konica Corp | 着色組成物、着色微粒子分散物、インクジェット用インク及びインクジェット記録方法 |
| EP1598349B1 (en) | 2003-02-13 | 2011-07-27 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
| CA2515190A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| WO2005012306A2 (en) | 2003-07-25 | 2005-02-10 | Neurogen Corporation | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| WO2005018532A2 (en) | 2003-08-25 | 2005-03-03 | Actar Ab | Purine receptor binding compounds |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP4204441B2 (ja) | 2003-10-31 | 2009-01-07 | ゲイツ・ユニッタ・アジア株式会社 | 寿命予知可能なタイミングベルト及びその製造方法 |
| WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| US20080004269A1 (en) | 2004-11-04 | 2008-01-03 | Yuelian Xu | Pyrazolylmethy Heteroaryl Derivatives |
| TW200638882A (en) | 2005-02-04 | 2006-11-16 | Senomyx Inc | Molecules comprising linked organic moieties as flavor modifiers for comestible compositions |
| US7968703B2 (en) * | 2005-03-07 | 2011-06-28 | Shire Canada Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
| EP1894931A1 (en) | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
| JP5336375B2 (ja) * | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| CA2691448A1 (en) * | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| BRPI0909945A2 (pt) | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
-
2007
- 2007-10-10 GB GBGB0719803.9A patent/GB0719803D0/en not_active Ceased
-
2008
- 2008-10-10 DK DK08806565.1T patent/DK2217578T5/da active
- 2008-10-10 WO PCT/GB2008/003428 patent/WO2009047514A1/en not_active Ceased
- 2008-10-10 PL PL08806565T patent/PL2217578T3/pl unknown
- 2008-10-10 US US12/679,871 patent/US8431596B2/en not_active Expired - Fee Related
- 2008-10-10 ES ES08806565.1T patent/ES2446298T3/es active Active
- 2008-10-10 HR HRP20140191AT patent/HRP20140191T1/hr unknown
- 2008-10-10 SI SI200831148T patent/SI2217578T1/sl unknown
- 2008-10-10 EP EP08806565.1A patent/EP2217578B9/en not_active Revoked
- 2008-10-10 PT PT88065651T patent/PT2217578E/pt unknown
-
2013
- 2013-04-24 US US13/869,374 patent/US9012633B2/en active Active
-
2014
- 2014-02-24 CY CY20141100147T patent/CY1114911T1/el unknown
-
2015
- 2015-03-16 US US14/658,437 patent/US9394301B2/en not_active Expired - Fee Related
-
2016
- 2016-06-20 US US15/186,689 patent/US9771362B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8431596B2 (en) | 2013-04-30 |
| US20100298339A1 (en) | 2010-11-25 |
| US20140155594A1 (en) | 2014-06-05 |
| GB0719803D0 (en) | 2007-11-21 |
| EP2217578A1 (en) | 2010-08-18 |
| US9012633B2 (en) | 2015-04-21 |
| US9394301B2 (en) | 2016-07-19 |
| WO2009047514A1 (en) | 2009-04-16 |
| US20170066762A1 (en) | 2017-03-09 |
| DK2217578T3 (da) | 2014-02-03 |
| ES2446298T9 (es) | 2014-09-29 |
| CY1114911T1 (el) | 2016-12-14 |
| EP2217578B1 (en) | 2013-12-04 |
| DK2217578T5 (da) | 2014-11-10 |
| HRP20140191T1 (hr) | 2014-04-25 |
| US9771362B2 (en) | 2017-09-26 |
| SI2217578T1 (sl) | 2014-03-31 |
| ES2446298T3 (es) | 2014-03-07 |
| PT2217578E (pt) | 2014-02-17 |
| EP2217578B9 (en) | 2014-09-10 |
| US20150246915A1 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2217578E (pt) | Compostos de [1,2,4]triazolo[1,5-a]piridina e [1,2,4]triazolo[1,5-c]pirimidina e a sua utilização | |
| HUS2400038I1 (hu) | Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok | |
| ZA201004368B (en) | Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors | |
| ZA200809796B (en) | Pyrazolo [1,5-A]pyrimidines as CDK inhibitors | |
| AP3417A (en) | Pyrazolo [1,5-a] pyrimidines as antiviral agents | |
| ZA201004524B (en) | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use | |
| ZA201101701B (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
| ZA201204028B (en) | Imidazo[1.2-a]pyridine compounds, sysnthesis thereof, and methods of using same | |
| IL206820A0 (en) | 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors and their syntheses | |
| BRPI0822237A2 (pt) | Compostos de imidazo [1,2-a] piridina | |
| ZA201202025B (en) | INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLO[2,3-b] PYRIDINE DERIVATIVES | |
| ZA201004823B (en) | Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents | |
| PL2124944T3 (pl) | Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy | |
| IL219371A (en) | Ethylene History - (s-Triazolo / Pyrzolo) [a – 5,1] (Pyridine / Pyrimidine) and Pharmaceuticals Containing Them | |
| EP2142542A4 (en) | NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704 | |
| BRPI0822239A2 (pt) | Composto de pirazolo[1,5-a] pirimidina | |
| IL198239A0 (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a] pyrimidin -6- one and 8-piperidinyl-2- pyrimidinyl [1,2-a] pyrimidin -6- one derivatives | |
| IL202471A0 (en) | Triazolo [1, 5-a] quinolines as adenosine a3 receptor ligands | |
| IL195949A0 (en) | Use of derivatives of imidazo[1,2-a]pyridine-2-carboxamides in therapeutics | |
| ZA201008178B (en) | Imidazo [2,1-b]quinazolin-2-one derivatives and their use as platelet anti-aggregative agents | |
| PL2059521T3 (pl) | Pirazolo[1,5-A]pirymidyny,sposoby, zastosowanie i kompozycje | |
| GB2454549B (en) | Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect | |
| GB0714815D0 (en) | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors |